{{Medical small}}
{{NoteTA|G1=Chemistry|G2=Medicine}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 596899008
| INN = Dexamfetamine
| IUPAC_name = (2''S'')-1-phenylpropan-2-amine
| image = D-amphetamine.svg
| width = 300px
<!-- Clinical data -->
| drug_name = 
| tradename = <!--Dexedrine, Metamina, Attentin, Zenzedi, Procentra, Amfexa-->
| Drugs.com = {{drugs.com|monograph|dextroamphetamine}}
| MedlinePlus = a605027
| licence_EU =
| licence_US = Dextroamphetamine
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S8
| legal_CA = Schedule I
| legal_DE = Anlage III
| legal_UK = Class B
| legal_US = Schedule II
| legal_status =
| dependency_liability =[[生理依赖|生理依赖]]：无<br />[[精神依赖|精神依赖]]：中
| addiction_liability = 中
| routes_of_administration = [[口服给药|口服]]
<!-- Pharmacokinetic data -->
| bioavailability = Oral 75–100%<ref>{{cite encyclopedia| title=Dextromphetamine | url=http://www.drugbank.ca/drugs/DB01576#pharmacology | work=DrugBank | accessdate=2013-11-05 | section=Pharmacology }}</ref>
| protein_bound = 15–40%
| metabolism = [[CYP2D6|CYP2D6]]，[[多巴胺β羟化酶|多巴胺β羟化酶]]，<ref name="DBH ref">{{cite book | title=Foye's Principles of Medicinal Chemistry | year=2013 | publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins | location=Philadelphia | isbn=1609133455 | page=648 |vauthors=Lemke TL, Williams DA, Roche VF, Zito W |edition=7th | quote=Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine.}}</ref> {{tsl|en|Flavin-containing monooxygenase||FMO3}}
| onset = {{abbr|IR|Immediate release}}服用：0.5至1.5小时<ref>{{Cite book|title = Primary Care Pediatrics|url = https://books.google.com/books?id=o43u_qWT4asC|publisher = Lippincott Williams & Wilkins|date = 2001-01-01|isbn = 9780781720083|first = Carol|last = Green-Hernandez|first2 = Joanne K.|last2 = Singleton|first3 = Daniel Z.|last3 = Aronzon|page = 243}}|quote = Table 21.2 Medications for ADHD ... D-amphetamine ... Onset: 30 min.</ref><ref>{{cite web|title = Dexedrine, ProCentra(dextroamphetamine) dosing, indications, interactions, adverse effects, and more|url = http://reference.medscape.com/drug/dexedrine-procentra-dextroamphetamine-342998#10|website = reference.medscape.com|accessdate = 2015-10-04|quote = Onset of action: 1–1.5 hr}}</ref><br />{{abbr|XR|Extended release}}服用：1.5至2小时<ref name="Millichap: onset, peak, and duration">{{cite book | author = Millichap JG |  editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York, USA | isbn = 9781441913968 | page = 112 | edition = 2nd | chapter = Chapter 9: Medications for ADHD | quote = <br />Table 9.2 Dextroamphetamine formulations of stimulant medication<br />Dexedrine [Peak:2–3 h] [Duration:5–6 h] ...<br />Adderall [Peak:2–3 h] [Duration:5–7 h]<br />Dexedrine spansules [Peak:7–8 h] [Duration:12 h] ...<br />Adderall XR [Peak:7–8 h] [Duration:12 h]<br />Vyvanse [Peak:3–4 h] [Duration:12 h]}}</ref><ref name="XR onset-duration">{{cite journal | vauthors = Brams M, Mao AR, Doyle RL | title = Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder | journal = Postgrad. Med. | volume = 120 | issue = 3 | pages = 69–88 | date = September 2008 | pmid = 18824827 | doi = 10.3810/pgm.2008.09.1909 | quote = Onset of efficacy was earliest for d-MPH-ER at 0.5 hours, followed by d, l-MPH-LA at 1 to 2 hours, MCD at 1.5 hours, d, l-MPH-OR at 1 to 2 hours, MAS-XR at 1.5 to 2 hours, MTS at 2 hours, and LDX at approximately 2 hours. ... MAS-XR, and LDX have a long duration of action at 12 hours postdose}}</ref>
| elimination_half-life =9至11小时<ref name="Adderall IR">{{cite web | title=Adderall IR Prescribing Information | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011522s042lbl.pdf | publisher = Teva Pharmaceuticals USA, Inc. | work = United States Food and Drug Administration | date=October 2015 | accessdate=2016-05-18 | pages=1–6}}</ref><br />不同的[[PH值|PH值]]：8至31小时
| duration_of_action = {{abbr|IR|Immediate release}}服用：3至7小时<ref name="Millichap: onset, peak, and duration" /><ref name="Narcolepsy guide">{{cite journal | vauthors = Mignot EJ | title = A practical guide to the therapy of narcolepsy and hypersomnia syndromes | journal = Neurotherapeutics | volume = 9 | issue = 4 | pages = 739–752 | date = October 2012 | pmid = 23065655 | pmc = 3480574 | doi = 10.1007/s13311-012-0150-9 }}</ref><br />{{abbr|XR|Extended release}}服用：12小时<ref name="Millichap: onset, peak, and duration" /><ref name="XR onset-duration" /><ref name="Narcolepsy guide"/>
| excretion = 肾（45%）；<ref>{{cite web|title=dextrostat (dextroamphetamine sulfate) tablet [Shire US Inc.]|publisher=Shire US Inc.|work=DailyMed|url=http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=1645|date=August 2006|accessdate=2013-11-08|location=Wayne, PA}}</ref>取决于尿液的pH值
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-64-9
| ATC_prefix = N06
| ATC_suffix = BA02
| ATC_supplemental =
| PubChem = 5826
| IUPHAR_ligand = 2147
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01576
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5621
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TZ47U051FI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03740
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4469
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 612
| synonyms =
<!-- Chemical data -->
| chemical_formula =
| C=9 | H=13 | Ag= | As= | Au= | B= | Bi= | Br= | Cl= | Co= | F= | Fe= | Gd= | I=
| K= | Mn= | N=1 | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=
| molecular_weight = 135.20622
| smiles = C[C@@H](Cc1ccccc1)N
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
| StdInChI_comment =
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KWTSXDURSIMDCE-QMMMGPOBSA-N
| density = 0.913
| melting_point =
| melting_notes =
| boiling_point = 201.5
| boiling_notes =
| solubility = 20
}}

'''右旋安非他命'''（{{lang-en| Dextroamphetamine}}）{{#tag:ref|其他英文名称：'''dexamphetamine''' （{{tsl|en|Australian Approved Name|AAN}}）、'''dexamfetamine''' （[[国际非专利药品名称|国际非专利药品名称]]和{{tsl|en|British Approved Name|BAN}}）、{{nowrap|'''(''S'')-amphetamine'''}}、{{nowrap|'''(+)-amphetamine'''}}、{{nowrap|'''<small>D</small>-amphetamine'''}}。| group = "注" }}是强力[[中樞神經系統|中樞神經]][[兴奋剂|兴奋剂]]，也是[[苯丙胺|苯丙胺]]（“安非他命”） 的[[对映异构|对映异构体]]，是[[注意力不足過動症|注意力不足過動症]]（ADHD）和[[發作性嗜睡病|發作性嗜睡病]]的处方药。<ref name="Dexedrine">{{cite web | title=Dexedrine Prescribing Information | work=United States Food and Drug Administration | publisher=Amedra Pharmaceuticals LLC | date=February 2015 | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdf | accessdate = 2015-09-04 | pages=1–7}}</ref>此外，它也被用作提升运动员能力的兴奋剂，也是一种[[益智药|益智药]]，同时人们在享乐时也将其用作[[春药|春药]]和[[欣快|产生欣快感的药]]。此外，空军也将右旋安非他命广泛用作“抗睡丸”，在诸如夜间轰炸之类的容易疲倦的任务中使用。[[第二次世界大战|第二次世界大战]]期间，该药物也被用来治疗疲倦。

==脚注==
<references group="注" />

==参考资料==
{{reflist}}

{{ADHD_pharmacotherapies}}
[[Category:药物|Category:药物]]
[[Category:兴奋剂|Category:兴奋剂]]
[[Category:苯丙胺类|Category:苯丙胺类]]
[[Category:作用于神经系统的药物|Category:作用于神经系统的药物]]